Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression

Genna M. Luciani, Lihua Xie, David Dilworth, Anne Tierens, Yoni Moskovitz, Alex Murison, Magdalena M. Szewczyk, Amanda Mitchell, Mathieu Lupien, Liran Shlush, John E. Dick, Cheryl H. Arrowsmith, Dalia Barsyte-Lovejoy, Mark D. Minden

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Acute myeloid leukemia (AML) is a complex, heterogeneous disease with variable outcomes following curative intent chemotherapy. AML with inv(3) is a genetic subgroup characterized by a very low response rate to current induction type chemotherapy and thus has among the worst long-term survivorship of the AMLs. Here, we describe OCI-AML-20, a new AML cell line with inv(3) and deletion of chromosome 7; the latter is a common co-occurrence in inv(3) AML. In OCI-AML-20, CD34 expression is maintained and required for repopulation in vitro and in vivo. CD34 expression in OCI-AML-20 shows dependence on the co-culture with stromal cells. Transcriptome analysis indicates that the OCI-AML-20 clusters with other AML patient data sets that have poor prognosis, as well as other AML cell lines, including another inv(3) line, MUTZ-3. OCI-AML-20 is a new cell line resource for studying the biology of inv(3) AML that can be used to identify potential therapies for this poor outcome disease.

Original languageEnglish
Pages (from-to)27-36
Number of pages10
JournalExperimental Hematology
StatePublished - Jan 2019
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018


Dive into the research topics of 'Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression'. Together they form a unique fingerprint.

Cite this